X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AUROBINDO PHARMA ALEMBIC PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 23.6 14.1 167.5% View Chart
P/BV x 6.2 3.6 170.5% View Chart
Dividend Yield % 0.8 0.4 177.0%  

Financials

 ALEMBIC PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
AUROBINDO PHARMA
Mar-17
ALEMBIC PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs792895 88.5%   
Low Rs443622 71.2%   
Sales per share (Unadj.) Rs167.0254.6 65.6%  
Earnings per share (Unadj.) Rs38.239.3 97.2%  
Cash flow per share (Unadj.) Rs42.046.6 90.2%  
Dividends per share (Unadj.) Rs4.002.50 160.0%  
Dividend yield (eoy) %0.60.3 196.6%  
Book value per share (Unadj.) Rs84.9160.0 53.1%  
Shares outstanding (eoy) m188.52585.88 32.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.73.0 124.1%   
Avg P/E ratio x16.219.3 83.8%  
P/CF ratio (eoy) x14.716.3 90.3%  
Price / Book Value ratio x7.34.7 153.4%  
Dividend payout %10.56.4 164.7%   
Avg Mkt Cap Rs m116,383444,390 26.2%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m4,21417,678 23.8%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m31,487149,157 21.1%  
Other income Rs m551,159 4.8%   
Total revenues Rs m31,542150,316 21.0%   
Gross profit Rs m10,06034,343 29.3%  
Depreciation Rs m7224,276 16.9%   
Interest Rs m37667 5.5%   
Profit before tax Rs m9,35630,558 30.6%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1607,597 28.4%   
Profit after tax Rs m7,19423,012 31.3%  
Gross profit margin %31.923.0 138.8%  
Effective tax rate %23.124.9 92.9%   
Net profit margin %22.815.4 148.1%  
BALANCE SHEET DATA
Current assets Rs m15,06692,062 16.4%   
Current liabilities Rs m7,67466,223 11.6%   
Net working cap to sales %23.517.3 135.5%  
Current ratio x2.01.4 141.2%  
Inventory Days Days67106 63.2%  
Debtors Days Days4168 60.0%  
Net fixed assets Rs m8,23762,919 13.1%   
Share capital Rs m377586 64.3%   
"Free" reserves Rs m15,41693,133 16.6%   
Net worth Rs m16,00593,719 17.1%   
Long term debt Rs m01,814 0.0%   
Total assets Rs m24,594162,494 15.1%  
Interest coverage x255.246.8 545.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.9 139.5%   
Return on assets %29.414.6 201.8%  
Return on equity %44.924.6 183.1%  
Return on capital %58.732.7 179.2%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81175,838 23.5%   
Fx outflow Rs m5,31830,224 17.6%   
Net fx Rs m12,49345,613 27.4%   
CASH FLOW
From Operations Rs m9,30432,786 28.4%  
From Investments Rs m-3,105-17,870 17.4%  
From Financial Activity Rs m-1,959-19,153 10.2%  
Net Cashflow Rs m4,240-4,239 -100.0%  

Share Holding

Indian Promoters % 74.1 54.1 137.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 8.0 36.5%  
FIIs % 9.1 27.7 32.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.2 136.3%  
Shareholders   49,328 69,601 70.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; Infosys & ICICI Bank Top Gainers(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.5% while the Hang Seng is also down 0.5%.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 20, 2018 12:25 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS